8-K: Delcath Systems Reports Profitable First Quarter 2025 Driven by Strong HEPZATO Sales

Delcath Systems announces a profitable first quarter in 2025, driven by significant revenue growth from HEPZATO KIT sales and expansion of treatment centers.

Summary

• Delcath Systems reported its first quarter 2025 financial results and business highlights.
• Total revenue reached $19.8 million, a significant increase from $3.1 million in the first quarter of 2024.
• HEPZATO KIT revenue was $18.0 million, compared to $2.0 million in the same period last year.
• CHEMOSAT revenue also increased to $1.8 million from $1.1 million in the first quarter of 2024.
• The company achieved a gross margin of 86%, up from 71% in the prior year's quarter.
• Delcath reported a net income of $1.1 million, a substantial improvement from a net loss of $11.1 million in the first quarter of 2024.
• Non-GAAP adjusted EBITDA was positive at $7.6 million, compared to a loss of $7.3 million in the first quarter of 2024.
• Cash and investments stood at $58.9 million as of March 31, 2025.
• The company generated $2.2 million in cash from operations during the quarter.
• Delcath activated three new U.S. centers in Q1 and two more in early Q2, bringing the total to 19 active centers with 10 additional referral centers.
• The FDA cleared an IND application for a Phase 2 clinical trial of HEPZATO in liver-dominant metastatic breast cancer.
• A comparative analysis from the randomized portion of the FOCUS Study in metastatic uveal melanoma was published.
• The exercise of Series F warrants resulted in $16.2 million of funding in 2025.

Sentiment

Score: 8

Explanation: The document presents a highly positive outlook with strong financial results, successful product commercialization, and promising clinical developments. The company's achievement of profitability and positive cash flow significantly boosts investor confidence.

Positives

• Significant revenue growth driven by HEPZATO KIT sales.
• Improved gross margins indicate better cost management and pricing strategies.
• The company achieved net income and positive operating cash flow for the first time.
• Strong cash position provides financial flexibility for future growth initiatives.
• Expansion of active treatment centers increases market reach and accessibility of HEPZATO.
• FDA clearance for a Phase 2 clinical trial opens up potential new indications for HEPZATO.
• The exercise of warrants provided a significant capital infusion of $16.2 million.

Negatives

• Research and development expenses increased to $5.0 million from $3.7 million due to clinical trial costs.
• Selling, general, and administrative expenses rose to $11.3 million from $8.8 million due to commercial expansion activities.

Risks

• The company's commercialization plans and ability to successfully commercialize the HEPZATO KIT are subject to uncertainties.
• Maintaining a successful HEPZATO KIT supply chain, including securing adequate supply of critical components, is crucial.
• Successful FDA inspections of the company's and its third-party suppliers' facilities are necessary.
• Effective implementation and management of the HEPZATO KIT Risk Evaluation and Mitigation Strategy (REMS) are essential.
• The company's ability to obtain reimbursement for the HEPZATO KIT is subject to uncertainty.
• Entering into necessary purchase and sale agreements with users of the HEPZATO KIT is critical for revenue generation.

Future Outlook

The company aims to continue its revenue growth and expand the adoption of HEPZATO for patients with metastatic uveal melanoma, while also pursuing expanded indications for HEPZATO.

Management Comments

• 'Consistent revenue growth and the continued expansion of active treatment centers represent a strong start to 2025,' said Gerard Michel, Chief Executive Officer of Delcath.
• He also stated that the company achieved its first quarter of net income and positive operating cash flow, underscoring the accelerating clinical adoption of HEPZATO for patients with metastatic uveal melanoma.
• Ongoing dialogue with oncologists and interventional radiologists reinforces the importance of whole-liver treatment for patients with liver-dominant disease, shaping the company's development strategy.

Industry Context

Delcath's focus on interventional oncology and liver-directed therapies positions it within a growing market for targeted cancer treatments. The company's HEPZATO KIT competes with other liver-directed therapies and systemic treatments for metastatic uveal melanoma and other liver cancers. The expansion of treatment centers and positive clinical data support the company's competitive position.

Comparison to Industry Standards

• Comparing Delcath's 86% gross margin to other specialty pharmaceutical companies like Exact Sciences (around 75%) or Guardant Health (around 65%) suggests strong pricing power or cost management.
• Delcath's shift to positive EBITDA is a key milestone, as many biotech companies like Adaptimmune or Iovance Biotherapeutics often operate at a loss while investing in R&D.
• The $16.2 million capital raise through warrant exercises strengthens Delcath's balance sheet, similar to how companies like BioNTech have used capital raises to fund expansion and clinical trials.

Stakeholder Impact

• Shareholders will benefit from the improved financial performance and growth prospects.
• Employees may see increased job security and opportunities due to the company's success.
• Patients will have greater access to HEPZATO through the expansion of treatment centers.
• Suppliers may experience increased demand for their products and services.
• Creditors will have greater confidence in the company's ability to meet its obligations.

Next Steps

• Continue commercial expansion activities, including marketing and personnel additions.
• Advance the Phase 2 clinical trial evaluating HEPZATO in combination with standard of care for mCRC.
• Pursue expanded indications for HEPZATO based on insights from oncologists and interventional radiologists.

Key Dates

Keywords

HEPZATO KIT, Delcath Systems, Metastatic Uveal Melanoma, Liver Cancer, CHEMOSAT, Financial Results, EBITDA, Revenue, Clinical Trial, FDA